Illumina Accelerator

Pandora Biosciences operates as a neuroscience company.

Nusantics is a biotechnology company based in Jakarta, Indonesia, founded in 2019. It specializes in precision molecular diagnostics, utilizing PCR and Next Generation Sequencing technologies to enhance healthcare outcomes for both humans and animals. The company offers a variety of products, including single pathogen and syndromic molecular diagnostics, as well as microbiome diagnostics. Nusantics focuses on improving diagnostics for respiratory, reproductive health, and blood-borne pathogens, particularly in low- and middle-income countries. Additionally, it analyzes microbiome profiles applicable to the skincare, personal care, food, and beverage industries, contributing to a holistic approach in health and wellness.

Terrapeutics Pharma specializes in drug discovery, utilizing an innovative platform that screens for therapeutic molecules derived from soil. This technology is grounded in the principles of nature, allowing for the identification of small therapeutic molecules aimed at addressing challenging medical targets. The company's focus includes the development of inhibitors for the ascending reticular activating system (RAS), as well as advancing drug discovery for infectious diseases. Through this approach, Terrapeutics aims to provide healthcare professionals with effective tools for combating various health challenges.

Dama Health specializes in pharmacogenetic technology aimed at providing personalized contraception recommendations for women and clinicians. The company employs genetic testing and an automated matching system that considers individual preferences, medical history, and specific requirements. By analyzing unique predispositions and the efficacy and side effect profiles of various contraceptive options, Dama Health enables women and healthcare providers to make informed and safe birth control decisions tailored to each individual's needs.

Viridian Seeds creates super-legumes to provide a sustainable source of healthy, nutritious plant proteins.

Acrobat Genomics is a company focused on drug discovery through innovative gene editing techniques. It employs high-throughput CRISPR technology to develop a range of new therapeutic options targeting various diseases. By utilizing its precision gene editing capabilities, Acrobat Genomics aims to enhance the availability of effective treatments, thereby supporting medical professionals in their efforts to improve patient care.

CRISP-HR a therapeutics company has developed a proprietary, next-generation CRISPR platform to create novel therapeutics for rare diseases.

Rethink Bio is a synthetic biology company from India, is focused on harnessing the potential of microalgae to develop sustainable food solutions to benefit the planet and people.

Cache is a biotechnology company focused on developing a groundbreaking wet operating system designed for the storage, access, and computation of biomolecules at scale. By ensuring the integrity and fidelity of nucleic acids from various sources, Cache enables researchers and partners to accelerate molecular pathology research and gain insights into life sciences. This innovative approach facilitates the analysis of biomolecules, thereby unlocking new precision medicine applications and enhancing the capacity for understanding biological data. Ultimately, Cache aims to make both digital and biological data universally accessible and sustainable, eliminating the need for data deletion or disposal.

B4X, INC., a therapeutics and diagnostics company from Atlanta, Georgia, is utilizing multi-omic big data anchored in genomics to deliver life-saving therapeutics and precision diagnostics to individuals suffering from debilitating diseases of the brain.

Purpose Health, Inc. a mental wellness company from Northern Virginia, supports consumers on their mental wellness journey with data-driven insights into the physiological impact of stress on the microbiome and body.

NonExomics is a healthcare data analytics company focused on diagnosing and curing diseases. The company employs proprietary machine learning techniques to integrate genomics, transcriptomic, and proteomics data. This integration allows NonExomics to predict the structures of nonexomic proteins and to identify disease-specific nonexomic targets. By doing so, NonExomics aims to assist researchers in discovering cures for rare diseases, thereby contributing to advancements in medical science and healthcare solutions.

4SR Biosciences Inc. is a diagnostics and therapeutics company emerging from the University of Chicago that focuses on developing innovative tRNA-based modalities for identifying disease biomarkers and advancing cancer therapeutics. The company employs a proprietary platform that utilizes RNA sequencing technology to analyze cellular tRNA, its fragments, and modifications derived from various clinical samples, including tissue, biofluids, and nasal swabs. This approach allows researchers to assess and compare the biological properties of numerous microbes with distinct tRNA genes, facilitating early detection of cancer. Through its work, 4SR Biosciences aims to contribute significantly to the fields of diagnostics and treatment in oncology.

Epicombi.AI is a spinout from Oxford University focused on developing innovative therapeutics for complex cancers, particularly pancreatic cancer. The company utilizes an artificial intelligence and machine learning-driven platform to analyze genomic datasets, filtering disease-related information to generate drug predictions. By identifying key signals and associated targets, Epicombi.AI aims to create multi-targeted drugs that can overcome epigenetic barriers in cancer treatment. This approach enhances the efficiency of drug discovery, ultimately benefiting patients facing intractable cancers.

Genegoggle is a biotechnology company focused on precision medicine, aiming to enhance human health through the discovery of novel therapeutics and intelligent systems. The company specializes in creating advanced particles that can effectively differentiate between cancerous and healthy cells. By utilizing multi-dimensional genomic and epigenetic data, Genegoggle develops innovative tools for drug discovery, employing artificial intelligence to design next-generation compounds. This approach enables the development of targeted therapies that specifically attack cancer cells while minimizing harm to healthy tissues, ultimately providing patients with access to groundbreaking treatments and diagnostic systems to improve their overall health.

Solena is a biotechnology company focused on enhancing agricultural productivity through the study of soil microbiomes. By developing biological capital technologies, Solena aims to improve farmers' profitability by providing tailored biological inputs that help preserve and calibrate soil diversity. The company offers sampling kits that measure and appraise the biological health of soils, giving farmers access to valuable insights and tools for sustainable farming practices. This approach supports environmentally friendly agriculture while addressing the challenges faced by modern farmers.

ImYoo is developing a patient-centric biodiscovery platform that focuses on generating scalable, high-fidelity longitudinal data. The company's innovative approach combines high-resolution assays with the convenience of home self-collection, allowing users to obtain single-cell multi-omic analysis from small blood volumes. This capability enables the identification of critical biomarkers over time and during significant health events, such as autoimmune flares or adverse effects from treatments. By prioritizing patient engagement and accessibility, ImYoo aims to enhance the understanding of health conditions and improve patient outcomes.

Bixbio is a biotechnology company focused on harnessing diverse genetic data from Africa to advance precision medicine. The company employs artificial intelligence and machine learning technologies to curate extensive genetic datasets, which aid in identifying disease-causing genetic variants and discovering novel drug targets. By leveraging this rich genetic information, Bixbio aims to support researchers in developing innovative solutions that enhance the field of precision medicine.

NewStem is a Jerusalem-based biotechnology company focused on enhancing the effectiveness of chemotherapy through its innovative precision-medicine technology. As a spinoff of Yissum, the Technology Transfer Company of The Hebrew University, NewStem specializes in predicting patient resistance to chemotherapy, enabling more targeted and effective cancer treatments. The company employs a platform that leverages synthetic lethal interaction for the discovery and development of anti-cancer therapies, along with bioinformatics-based software designed as a medical device. This approach aims to support medical researchers in advancing regenerative medicine, disease therapy, and cancer research, ultimately contributing to improved patient outcomes in oncology.

Yali Biosciences is a food technology company focused on creating sustainable, climate-smart foods through the application of synthetic biology and genomics. Utilizing a synthetic biology platform, the company designs and develops fats tailored for alternative dairy products, which allows the food industry to produce delicious and environmentally friendly dairy alternatives. By leveraging computational biology, Yali Biosciences aims to transform food production processes, promoting renewable resources and supporting the shift towards more sustainable food options.

Powered by genomics, skin microbiome science, and machine learning, Parallel is an end-to-end next-generation skin health company providing derm telehealth, cutting-edge skin microbiome diagnostics, precision microbiome skincare, and personalized Rx

Broken String Biosciences is focused on creating a sequencing platform that enhances the assessment of genome stability, aiming to facilitate the development of safer cell and gene therapies. The company integrates advanced sequencing techniques with bioinformatics and artificial intelligence, enabling healthcare professionals to utilize a data-driven approach for the safe introduction of innovative medicines. Through its novel tools, Broken String Biosciences seeks to unlock advancements in therapeutic options, contributing to the evolution of medical treatments.

Flightpath Biosciences is a biotechnology company based in Berkeley, California, founded in 2019. It specializes in developing innovative therapies aimed at treating rare infectious diseases, particularly those caused by pathogenic bacteria. The company's focus includes antibiotic therapies that target co-infectious bacteria in conditions such as Lyme disease, aiming to reduce microbiome damage and address multiple pathogenic bacteria in both the oral and gut microbiomes. By collaborating with leading scientists and experts in therapeutics and diagnostics across various academic institutions and government agencies, Flightpath Biosciences is committed to exploring diverse fields of biology to create novel and targeted treatment solutions.

MultiplAI Health specializes in developing advanced blood screening tests aimed at detecting complex diseases, including cardiovascular disorders and cancers. Utilizing RNA sequencing and artificial intelligence, the company analyzes numerous biomarkers in blood samples to facilitate early diagnosis. Their innovative approach allows for universal remote screening, making it possible to conduct tests using simple blood samples that can be administered anywhere, at a significantly lower cost compared to traditional diagnostic methods. This technology not only supports preventative screening for asymptomatic individuals but also aids in post-treatment monitoring, enabling clinicians to make more accurate prognoses and treatment decisions based on enhanced diagnostic stratification.

Rubik Therapeutics is a platform therapeutics company developing next gen cell therapies for solid tumors. Rubik's computational engine and genome scale discovery tools have identified a set of unique genetic modulators that endow immune cells (T and NK) with potent and selective anti-tumor activity.

Biotax specializes in providing advanced biological and genomic informatics solutions aimed at enhancing personalized medicine. The company focuses on microbiome genetics analysis, utilizing artificial intelligence to deliver comprehensive insights that assist healthcare providers in diagnosing and treating diseases more effectively. Founded by a team of prominent researchers, Biotax is committed to improving patient outcomes through the development of innovative diagnostics and treatment protocols for pharmaceutical companies, hospitals, and medical centers.

Oshun Medical is an innovative diagnostic and digital health company exclusively committed to advancing the health of women and championing awareness of their healthcare issues.

Algen Biotechnologies, Inc. is a therapeutic discovery company focused on drug development through an innovative platform that decodes functional gene networks. The company leverages advanced technologies, including CRISPR and machine learning, to uncover disease-driving RNA messages. By analyzing complex disease signaling and gene networks, Algen aims to facilitate drug discovery for cancer and other diseases with significant unmet medical needs. Its approach seeks to provide valuable insights for drug companies, enabling them to identify and develop effective treatments.

Biome Makers Inc. is a biotechnology company based in San Francisco, California, founded in 2015. The company specializes in understanding and identifying microbiomes, particularly in the context of agriculture. By utilizing DNA sequencing technologies and proprietary Intelligent Computing systems, Biome Makers provides detailed, crop-specific insights and recommendations to enhance agricultural production and product quality. Their technology enables growers and manufacturers to analyze soil ecosystems effectively, offering data-driven insights that facilitate improved decision-making in farming practices.

Trace Genomics, Inc. is a company focused on advancing soil health and microbiome analysis through artificial intelligence-based diagnostic tools designed for farmers. The company provides a soil microbiome test that utilizes DNA sequencing and a comprehensive database of microbial species to predict soil diseases, assess soil health, and enhance crop quality. By analyzing the microbial composition and diversity within soil samples, Trace Genomics offers valuable insights that empower farmers to make informed decisions regarding soil management, crop selection, and the application of fertilizers. Founded in 2015 and headquartered in Burlingame, California, with an additional office in Ames, Iowa, Trace Genomics aims to support sustainable agricultural practices by providing actionable information that enhances soil productivity and sustainability.

MetaMixis Inc. is a biotechnology company based in Vancouver, Canada, founded in 2012. The company focuses on developing enzymes and metabolic pathways for microorganisms that produce chemicals. MetaMixis creates biosensors that leverage natural environmental processes to detect biochemical transformations. Additionally, it screens diverse environmental DNA libraries to generate a portfolio of enzymes and pathways capable of performing specific transformations. The founding team combines expertise in synthetic biology, environmental genomics, and bioinformatics, with the goal of advancing the bioeconomy through innovative enzyme and pathway discovery. The company has also established a knowledgeable board to guide its development and growth.

Vitagene, Inc. is a health technology company that uses genomic science and advanced technology to create a DNA-based personalization platform for healthcare. It offers customized supplements directly to patients based on their individual needs for nutrition, sleep, exercise, and supplementation. The company's algorithm analyzes extensive patient data, including genetics, blood work, and lifestyle, to generate personalized supplement regimens. Vitagene also manufactures DNA health test kits and provides health and ancestry reports that outline dietary, supplement, and exercise recommendations. Additionally, the company produces at-home COVID-19 saliva test kits. Founded in 2014 and based in San Francisco, California, Vitagene aims to empower individuals with tailored health solutions through big data and machine learning.

NextGen Jane is a women's health company that utilizes a data-driven approach to enhance reproductive health insights. The company has developed a smart tampon system that allows users to conveniently mail in cells shed during menstruation for analysis. By employing patented tampon collection technology, NextGen Jane transforms biological signals from the reproductive tract, including the endometrium, cervix, fallopian tubes, and ovaries, into digital diagnoses. This innovative platform enables women to gain valuable information about their reproductive health and predict potential diseases through comprehensive sequencing analysis of their menstrual samples.

Biome Makers Inc. is a biotechnology company based in San Francisco, California, founded in 2015. The company specializes in understanding and identifying microbiomes, particularly in the context of agriculture. By utilizing DNA sequencing technologies and proprietary Intelligent Computing systems, Biome Makers provides detailed, crop-specific insights and recommendations to enhance agricultural production and product quality. Their technology enables growers and manufacturers to analyze soil ecosystems effectively, offering data-driven insights that facilitate improved decision-making in farming practices.

A genomics company, developing noninvasive urine-based nucleic acid sequencing diagnostics for the detection and monitoring of cancer.

Xcell Biosciences, Inc. is a San Francisco-based life science start-up founded in 2012, focused on developing innovative technologies for cancer cell analysis and immunotherapy. The company specializes in a bench-top primary cell control system that captures, grows, and analyzes cancer cells directly from patient blood samples. Their proprietary technology allows for precise control of primary cell phenotype and function, enhancing the efficacy and persistence of immune cell therapies. By supporting various primary cell types, including immune, stem, and tumor cells, Xcell Biosciences provides researchers with advanced tools for cell maintenance and expansion, ultimately aiming to improve therapy development and clinical outcomes.

Encoded Therapeutics, Inc. is a biotechnology company that specializes in precision gene therapies aimed at treating a wide array of severe genetic disorders. Utilizing a unique platform, Encoded identifies sequences within the human genome that regulate gene expression through advanced screening and computational techniques. The company's therapy pipeline targets both genetic and acquired disorders across various disease pathways, including neurocircuitry, liver and metabolic disorders, neurodegeneration, and cardiovascular diseases. Founded in 2014 and based in South San Francisco, California, Encoded Therapeutics is focused on developing innovative solutions that enable medical practitioners to improve patient outcomes and enhance quality of life.

EpiBiome, Inc. is a precision microbiome engineering company focused on developing therapies to combat infectious diseases in humans and agriculture without relying on small-molecule antibiotics. Founded in 2013 and based in South San Francisco, California, EpiBiome offers innovative phage therapy solutions that target specific strains within the microbiome, addressing issues such as antibiotic resistance and providing alternatives to traditional antibiotics. The company’s therapies are designed to treat conditions like mastitis in dairy cows and infections caused by Escherichia coli in humans. EpiBiome employs advanced sequencing and bioinformatic processes to identify pathogenic bacteria and microbiome alterations that may lead to disease, facilitating patient recovery and enhancing health outcomes. As of mid-2018, EpiBiome operates as a subsidiary of Locus Biosciences, Inc.